Granulomatosis With Polyangiitis Diagnosis Market Size, Share and Global Trend by Treatment (Blood Tests, Urinalysis, Imaging Tests, Biopsy), By End User (Hospitals, Clinics, Diagnostic Centers), and Regional Forecast, 2024-2032

Granulomatosis with Polyangiitis refers to a long term systemic disorder which includes the elements and symptoms of both, granulomatosis and polyangiitis. The disease is a variation of the autoimmune disease, vasculitis and affects a number of small and medium-size vessels in various organs in the body but particularly the kidneys and the upper respiratory tract. According to the National Institutes of Health (NIH), granulomatosis with polyangiitis affects an estimated 3 per 100,000 individuals’ in the U.S. The disorder can be diagnosed through a number of methods which includes blood tests, urine analysis and imaging tests amongst others. Some of the imaging tests are also critical for the monitoring of the prognosis of the disease and the understanding of the effects and results of the ongoing treatment. A number of key market players across a variety of diagnostic measures are present in the market and most of them are involved in the R&D of advanced diagnostic technologies such as the magnetic resonance imaging (MRI) systems of higher strengths. For instance, recent research has shown that the small dosage of radiotherapy is useful for the treatment of Granulomatosis with Polyangiitis and the MRI systems help in the understanding and the confirmation of this.

The growth in the number of technologically advanced diagnostic procedures and its availability in the developed and the emerging markets are expected to be one of the driving factors of this market. This includes the availability of superior and advanced imaging systems such as MRI, computed tomography (CT) and chest x-ray systems. This combined with the increased prevalence of the disorder in regions such as North America and Europe is expected to positively drive the market, due to the advanced healthcare systems in the regions and the heightened awareness of the disease. 

Some of the factors that might inhibit the growth of the Granulomatosis with Polyangiitis diagnosis market is the inability of certain individuals to undertake certain diagnostic procedures such as the MRI scans, where individuals with metallic implants amongst others are unable to undergo the procedures and certain individuals such as ones suffering from claustrophobia and are comparatively larger than the small opening of the MRI systems’ bore are also not able to undertake the test. Also, the costs associated with certain diagnostic procedures such as kidney biopsy are also quite expensive, if proper reimbursement policy is not applicable. 

Key Players Covered 

Some of the major companies that are present in the global Granulomatosis with Polyangiitis Diagnosis market are Siemens Healthcare GmbH, GE Healthcare, Koninklijke Philips N.V., Canon Inc., Hitachi, Ltd., Shimadzu Corporation and Fujifilm Corporation and other players. 

 SEGMENTATION 

At present, blood tests account for the largest proportion of the market due to their ability to detect the high level of C-reactive protein and also the high levels of erythrocyte sedimentation rate (ESR), which indicates the level of inflammation. Other diagnostic procedures such as imaging tests are also critical as they indicate the degree to which the blood vessels have been affected by the disorder. 

Key Insights 

• Prevalence of granulomatosis with polyangiitis


• Regulatory scenario for key countries


• Technological advancements in granulomatosis with polyangiitis diagnosis 

Regional Analysis: 

The global Granulomatosis with Polyangiitis Diagnosis market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for Granulomatosis with Polyangiitis Diagnosis at present and they are expected to account for a large proportion of the market in the forecast period as well. Due to the availability of advanced diagnostic technologies in these regions and the higher prevalence of the disorder in white individuals, the greater market share is dominated by these regions. In the Asia Pacific region, Japan is expected to provide the largest market opportunity. This is even after the relatively lesser occurrence of the disease in Japan compared to North America and Europe. The reason for Japan’s high share was due to the availability of technologically advanced diagnostic systems and also the highest concentration of MRI systems per any OECD nation amongst others, which can be related to the high level of diagnostic procedures. 

Key Industry Developments

• In October 2017, the Food and Drug Administration (FDA) cleared the first ever 7T MRI, which enables for the better imaging of the minute structures, thus enabling the better diagnostics for the granulomatosis with polyangiitis.


• Recent research and developments have led to the 3D imaging of the various kidney diseases, thus leading the way for the accurate diagnosis of the granulomatosis with polyangiitis for the kidneys.


• Better analytics in the blood tests for the measurement of the inflammation in the body such as the erythrocyte sedimentation rate, have led to the swift diagnosis of the disorder.